Compare Repligen Corporation Common Stock (RGEN) vs SSR Mining Inc. Common Stock (SSRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SSR Mining Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while SSR Mining Inc. Common Stock trades at $31 (market cap $6.72B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and SSR Mining Inc. Common Stock pays a 0.09% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SSR Mining Inc. Common Stock for 1 Days on average.
| RGEN | SSRM | |
|---|---|---|
Market Cap | $11.14B | $6.72B |
Volume | 1,259,263 | 3,758,896 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $39.21 |
52-Week Low | $102.87 | $19.48 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $11.02B | $4.89B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SSR Mining (SSRM) trades at $33.09, down 6.63% amid recent volatility, yet maintains strong fundamentals with a P/E of 12.44 and net income margin of 12.3%. The company recently announced the $464 million acquisition of Roxmore Resources, which could add 170,000 ounces of annual gold production. Technical indicators show a bullish trend with support at $34-$35, while earnings have beaten expectations in two of the last three quarters.
The outlook remains positive with a consensus price target of $42.67 (29% upside), driven by strategic acquisitions and Americas-focused growth. Risks include execution of the Roxmore integration and gold price sensitivity. Analysts are bullish (73% buy ratings), citing the company's debt-free balance sheet and $1.8 billion cash position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SSR Mining Inc. Common Stock
SSR Mining operates precious-metals mines in the United States, Canada, and Argentina. It produces gold doré and concentrates containing copper, silver, lead, and zinc.
Read more on SSRM →
